Again, to be fair, the dining choices around 420 Lexington Avenue are a lot more tempting than those around Binney Street. I bet Jacob eats a lot nicer lunches than Hecht. But then he has a lot more time on his hands.
Odd, how with their 464 employees, they're losing less money per quarter than Synergy with their 34 employees. While conducting a full slate of Phase I, II, and III trials.
This is not a fair comparison. If you have 464 employees in your own building situated midway between Harvard, MIT, and MGH, there are a lot of things you can do which 34 employees sitting upstairs from The Oyster Bar in Grand Central can't manage.
Utter fantasy. No facts. Synergy doesn't even have the cash to continue the IBS-C trials. And no partnerships, without which they will go broke. If this is the prettiest girl in town, how come she never has a date?
Like their stockholders, Synergy's 34 employees will be sitting around waiting for the phone to ring for the rest of the year. Hoping for a buyout offer or, if all goes well, FDA approval for CIC. They seem to have even put their IBS-C trials on hold.
Ironwood's 464 employees will be a lot busier. They have had FDA approval for both CIC and IBS-C for almost 3 1/2 years. So, in addition to marketing Linzess here and in Europe, they'll be...
1. Awaiting further Phase III trial results for the 72mg dose of linaclotide for pediatric use.
2. Awaiting Phase III results for opiod induced constipation.
3. Conducting trials for Linzess in nursing mothers, and two other studies which pave the way for the eventual removal of the black box warning.
4. Awaiting Phase III results for the colonic release formulation.
5. Conducting Phase II trials for IW-3718 for GERD (acid reflux).
6. Having conducted successful Phase III trials, awaiting Astellas's filing for marketing approval in Japan.
7. Having concluded successful Phase III trials, awaiting AstraZeneca's filling for marketing in China.
8. Conducting Phase III trials for Linzess in capsule endoscopy prep.
9. Conducting further trials on their new diagnostic tests to definitively diagnose IBS.
10. Continuing research on IW 1973 for orphan GI diseases, including diabetic gastroparesis.
11. Continuing research on IW 1701 for cardiovascular diseases.
12. Continuing research on the application of IW 3718 for Duchenne's muscular dystrophy.
Of course, they might also be waiting for the phone to ring.
I put in a market order(something I should know better than to do) for 500 shares when this was @15.22ask/15.35 bid. The order did not fill til 15.45. Look for this to go much higher.
In their most recent presentation, Ironwood stated that they would be cash flow positive by 2017. They also stated that they would not need any further financing for their continued rollout. Linzess should be on the market in Japan and China by the end of this year.
By smart money, I guess you mean teo_calderon, who I think just put down about $50 for a January call option. Every little bit helps.
This stock has little real connection to the overall market ...or even to the IBI, in my opinion. I own i5 biopharm stocks, and I bet that if the IBB bounces 6 points, 10 of them will radically outperform SGYP. IRWD will not be one of these.
I assume that they got caught frontrunning their own clients. If you think that it discouraged them in any way, put in a buy order for 1,000 shares of something not too heavily traded just above the bid and watch them try to jump ahead of you. The first couple of hours are so full of HFT churning, that I now usually wait a couple of hours before doing anything.
What trials does Synergy have in progress for their wonderful drugs, other than followups to the original CIC Phase III's? What partnerships have they signed?
The truly amazing thing is that I am handsomely paid by my Hedge Fund Masters to try and educate you 30 bozos. It's like getting a big grant from the Rockefeller Foundation to translate the Bible into a language spoken by a tribe of 30 Amazonian Indians. But it's a living.
Vanguard and Blackrock, as the major sellers of ETF's and index funds, own ALL biotech stocks. Sometimes, if they're weighted ETF's, they have to buy more when the stock goes down.
Shire isn't about to buy a company where their former employee is CFO. Valeant (remember back in July and August Betonbio was reporting that "the buzz' at the bio conferences was all about Valeant acquiring Synergy) is in the business of buying approved drugs, cutting R&D and raising their prices. They are not about to blow a billion $ bringing a me-too laxative to market. BMS got burned bigtime on their last Cerrone/Jacob acquisition. AstraZeneca is partnered with Ironwood for China and has spent a bundle on Phase III trials for Linzess. Pfizer is part of Allergan, Ironwood's major partner. They better find someone soon or the jig is up. Again, it's highly flattering that you post under an approximation of my id, which I assume carries the credibility which your own lacks.
Yes, millions of the constipated are sitting on the john waiting for the relief that might come in 2017 if this reaches market.